Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hutchmed Starts China Trial of Novel FGFR Inhibitor in Solid Tumor Cancers

publication date: Feb 4, 2022

Shanghai Hutchmed started a China Phase Ib/II study of its novel FGFR 1/2/3 inhibitor combined with chemotherapy or toripalimab, an anti-PD-1 therapy. The two-stage, open-label clinical trial will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy profile of HMPL-453 in patients with advanced or metastatic solid tumors. Hutchmed is also testing HMPL-453 as a monotherapy in patients with advanced intrahepatic cholangiocarcinoma . Toripalimab, a Shanghai Junshi Bio product, is the first China-developed PD-1 approved for use in China. More details....

Stock Symbols: (NSDQ/AIM: HCM; HK: 13) (HK: 1877; SHA: 688180)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.